{"id":"6d00ecbc-c97e-56e9-816d-bc3d6a4fecc6","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:six-months-at-high-dose-does-not-improve-global-cognition","predicate":"does_not_change","statement":"At 8,000 FU per day for six months there was no between-group difference in Montreal Cognitive Assessment change, with a mean difference of 0.038.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"be1df9ae-96dc-5690-b59c-dc8f8884fa4f","mechanism_event_label":"At 8,000 FU per day for six months there was no between-group difference in Montreal Cognitive Assessment change, with a mean difference of 0.038.","subject":{"id":"e8eb9bb4-3c6f-5e96-a968-a6d1fece71e7","slug":"nattokinase-supplement","display_name":"Commercial nattokinase supplement, composition study-specific","entity_type_key":"chemical_species"},"object":{"id":"474f1a65-db71-59a7-8f06-f07bc928ef8e","slug":"global-cognition-score","display_name":"Global cognition score, instrument specified by study","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"be1df9ae-96dc-5690-b59c-dc8f8884fa4f","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:six-months-at-high-dose-does-not-improve-global-cognition-event","event_type":"observed_intervention","label":"At 8,000 FU per day for six months there was no between-group difference in Montreal Cognitive Assessment change, with a mean difference of 0.038.","description":"Cognitive assessment with multimodal brain MRI","status":"provisional","compartment":null,"participants":[{"entity":{"id":"e8eb9bb4-3c6f-5e96-a968-a6d1fece71e7","slug":"nattokinase-supplement","display_name":"Commercial nattokinase supplement, composition study-specific","entity_type_key":"chemical_species"},"role":"acting component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"474f1a65-db71-59a7-8f06-f07bc928ef8e","slug":"global-cognition-score","display_name":"Global cognition score, instrument specified by study","entity_type_key":"cellular_process"},"role":"component the finding is about","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"6 months","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human (120 randomized, 88 completed, asymptomatic intracranial or carotid stenosis, mean age 58.3)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Nattokinase, 8,000 FU per day","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Double-blind, placebo-controlled and single-centre, with substantial attrition. The highest dose tested in any randomized trial here. A null on cognition does not test plaque or thrombotic endpoints, which is what the high-dose cohort studies report.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Human (120 randomized, 88 completed, asymptomatic intracranial or carotid stenosis, mean age 58.3)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"At 8,000 FU per day for six months there was no between-group difference in Montreal Cognitive Assessment change, with a mean difference of 0.038.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Nattokinase supplementation for cognitive enhancement in asymptomatic intracranial/carotid stenosis: A randomized controlled trial. (2026) https://pubmed.ncbi.nlm.nih.gov/41325794/ DOI: 10.1016/j.jstrokecerebrovasdis.2025.108511","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vivo, oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Cognitive assessment with multimodal brain MRI","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"a1d143a6-693d-595e-a532-f742ab0d960f","evidence_kind":"source_excerpt","locator":"Lines 1225-1225","start_line":1225,"end_line":1225,"excerpt":"At 8,000 FU per day for six months there was no between-group difference in Montreal Cognitive Assessment change, with a mean difference of 0.038.","model_system":"Human (120 randomized, 88 completed, asymptomatic intracranial or carotid stenosis, mean age 58.3)","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"41cb127c-1c23-53aa-b7d0-5ec7f6fa3c99","stable_key":"import-33bef151-bdc7-5892-aff6-0345ab149739","title":"Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23)","document_type":"imported_text","citation_label":"Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text.","file_path":"","sha256":"34fc46e0e849d06bfa13cb099a79b50679dd6fd0de8a5a0575326afdde3259c1","revision_id":"efd063e6-e982-5f6e-a4b8-6f2ffe4185ce","review_status":"unverified_draft","notes":""}}],"relations":[{"id":"cae3952e-549f-5e89-bc97-09684dfeaa5d","relation_type":"limits_translation_of","notes":"A null on human global cognition at the highest randomized dose stands against the animal neurology, though it tested a different population and a different endpoint.","source_claim_id":"6d00ecbc-c97e-56e9-816d-bc3d6a4fecc6","source_claim_key":"33bef151-bdc7-5892-aff6-0345ab149739:six-months-at-high-dose-does-not-improve-global-cognition","source_statement":"At 8,000 FU per day for six months there was no between-group difference in Montreal Cognitive Assessment change, with a mean difference of 0.038.","target_claim_id":"b20ed1b7-16c8-59c2-b334-e62af45b7692","target_claim_key":"33bef151-bdc7-5892-aff6-0345ab149739:oral-nattokinase-lowers-brain-amyloid-and-aluminium-accumulation","target_statement":"Oral nattokinase at 65 or 130 mg/kg per day improved aluminium and amyloid plaque accumulation in the brain and enhanced brain volume in a rat model."}],"conflicts":[],"corrections":[],"research":null}